Search
Velpatasvir
go.drugbank.com/drugs/DB11613ApprovedInvestigationalin combination with sofosbuvir for all six genotypes of Hepatitis C [L852]. … Both Canadian and American guidelines list Epclusa as a first line recommendation for all genotypes of HCV [L852, A19626].
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseAdefovir dipivoxil
go.drugbank.com/drugs/DB00718ApprovedAdefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseIbalizumab
go.drugbank.com/drugs/DB12698ApprovedInvestigationalThis drug was approved in March 2018 for the management of treatment-resistant HIV [L1554]. … In October 2022, the FDA approved the administration of Trogarzo (ibalizumab-uiyk) by intravenous push, allowing for a faster drug administration.[L43443,L43448]
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseTransient receptor potential cation channel subfamily V member 1
go.drugbank.com/bio_entities/BE0001023TargetHumansActs as ionotropic endocannabinoid receptor with central neuromodulatory effects. … Sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL.
Polypeptides: Transient receptor potential cation channel subfamily V member 1Synonyms: Capsaicin receptor, Vanilloid receptor 1Low affinity immunoglobulin gamma Fc region receptor II-a
go.drugbank.com/bio_entities/BE0002098TargetHumansLow affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens
Polypeptides: Low affinity immunoglobulin gamma Fc region receptor II-aSynonyms: IgG Fc receptor II-aTransient receptor potential cation channel subfamily V member 2
go.drugbank.com/bio_entities/BE0009158TargetHumansCalcium-permeable, non-selective cation channel (PubMed:10201375). Seems to be regulated, at least in part, by growth factors, such as IGF1, PDGF and morphogenetic neuropeptide/head activator. May transduce physical stimuli in mast cells...
Polypeptides: Transient receptor potential cation channel subfamily V member 2Synonyms: Vanilloid receptor-like protein 1Ankyrin repeat and protein kinase domain-containing protein 1
go.drugbank.com/bio_entities/BE0009411TargetHumansPolypeptides: Ankyrin repeat and protein kinase domain-containing protein 1Transient receptor potential cation channel subfamily M member 3
go.drugbank.com/bio_entities/BE0009808TransporterHumansSuggested to function as an ionotropic steroid receptor in beta-cell, indeed pregnenolone sulfate leads to Ca(2+) influx and enhanced insulin secretion.
Polypeptides: Transient receptor potential cation channel subfamily M member 3Synonyms: Long transient receptor potential channel 3Grepafloxacin
go.drugbank.com/drugs/DB00365ApprovedWithdrawnDue to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseOdevixibat
go.drugbank.com/drugs/DB16261ApprovedInvestigational[A236808,L34793] Odevixibat is the first approved non-surgical treatment option for PFIC.[L34803] Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid]. … Odevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC